Currently Viewing:
Newsroom
Currently Reading
Abeona Receives Breakthrough Designation for Rare Skin Disease Gene Therapy
August 31, 2017 – AJMC Staff
FDA Approves Tisagenlecleucel, the First CAR-T Cell Therapy in the United States
August 30, 2017 – Laura Joszt
Ancestry Determines Effective and Harmful Dose in Breast Cancer
August 28, 2017 – Surabhi Dangi-Garimella, PhD
Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial
August 25, 2017 – Surabhi Dangi-Garimella, PhD
Study Does Not Find Sufficient Evidence of Medicinal Cannabis Use for Chronic Pain
August 25, 2017 – Alison Rodriguez
Gender Differences in the Brain Explain Why Men Have Higher Rates of ADHD
August 24, 2017 – Alison Rodriguez
Study Finds HPV Vaccination Underutilized by Childhood Cancer Survivors
August 24, 2017 – Surabhi Dangi-Garimella, PhD
What Is the Ideal Age for Screening Mammography?
August 23, 2017 – Surabhi Dangi-Garimella, PhD
Probiotics Do Not Have a Significant Impact on Preventing Eczema, Asthma in Infants
August 23, 2017 – Alison Rodriguez

Abeona Receives Breakthrough Designation for Rare Skin Disease Gene Therapy

AJMC Staff
A gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disease that causes the skin to be very fragile and blister easily, has been granted Breakthrough Therapy designation status by the FDA.
A gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disease that causes the skin to be very fragile and blister easily, has been granted Breakthrough Therapy designation status by the FDA.

Abeona’s president and CEO, Timothy J. Miller, PhD, expressed gratitude at the FDA’s designation.

“EB-101 is an autologous gene-corrected cell therapeutic approach that utilizes a patient’s own cells and genetically engineering them to produce the correct version of collagen, which helps hold skin on to the body, thereby reducing the number of painful blisters caused by injury and improving wound healing,” Miller said in a statement.

The breakthrough designation was granted based on data from the phase 1/2 EB-101 clinical trial, which showed significant wound healing in treated wounds for more than 2 years after treatment. The designation, which is granted to drugs used to treat serious or life-threatening conditions, allows Abeona to expedite the development and review of EB-101.

RDEB is the most severe form of epidermolysis bullosa. EB-101 is a skin graft that includes a healthy COL7A1 gene, which is mutated in patients with RDEB.

In the phase 1/2 clinical trial, EB-101 was administered to non-healing chronic wounds on each subject. The wounds were assessed at predefined time points to determine wound healing, and the researchers found significant wound healing—defined as more than 75% closure—in 94% of patients at 3 months, 67% of patients at 6 months, and 50% of patients at 12 months.

When the trial results were released in April 2017, and presented at the Society for Investigative Dermatology in Portland, Oregon, Miller outlined the benefits of the treatment.

“The EB-101 clinical data update highlights the wound closure and collagen biomarker expression continues for over 2 years in multiple patients, which are critically important parameters of efficacy in patients with RDEB,” he said.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up